地高辛对老年慢性心衰患者血清CA125,BNP及MMP-9水平的影响  

Effect of the Serum Levels of CA125, BNP and MMP-9 by Digoxin Tablets in Elderly Patients with Chronic Heart Failure

作　　者：付爽[1] 高旋[1] 杨雪松[1] 张莹雪[1] 刘广旭[1] 

机构地区：[1]中国医科大学附属第四医院药剂科,辽宁沈阳110032

出　　处：《现代生物医学进展》2016年第12期2323-2326,共4页Progress in Modern Biomedicine

基　　金：辽宁省自然科学基金项目(20022059)

摘　　要：目的:探讨地高辛片对老年慢性心力衰竭患者血清血清糖类抗原(CA125)、心钠肽(ANP)、脑钠肽(BNP)、基质金属蛋白酶9(MMP-9)及金属蛋白酶组织抑制剂(TIMP-1)水平的影响。方法:收集我院老年慢性心力衰竭患者100例,随机分为对照组和实验组,每组各50例,对照组患者给予常规治疗,实验组患者在对照组的基础上给予地高辛片。比较治疗前后两组患者血清糖类抗原(CA125)、心钠肽(ANP)、脑钠肽(BNP)、基质金属蛋白酶9(MMP-9)及金属蛋白酶组织抑制剂(TIMP-1)水平。结果:与治疗前相比,两组患者血清CA125、ANP、BNP及MMP-9水平降低,TIMP-1水平升高(P<0.05);治疗后与对照组相比,实验组CA125水平(34.05±4.63)较低,ANP水平较低(216.98±27.65),BNP水平较低(437.62±45.26),MMP-9水平较低(550.17±65.15),TIMP-1水平较高(182.32±21.78)(P<0.05)。结论:地高辛片能够改善老年慢性心力衰竭患者心肌功能,推测其机制可能与降低血清CA125、ANP、BNP、MMP-9水平,升高TIMP-1水平有关。Objective： To investigate the effect of Digoxin tablets on the serum levels of CA125, BNP and MMP-9 in elderly patients with chronic heart failure. Methods： 100 elderly patients with chronic heart failure from our hospital were selected and randomly divided into the control group 50 cases and the experiment group 50 case. The control group were treated by conventional therapy and the experiment group were treated on the base of the control gorup with Digoxin tablets. The serum levels of CA125, BNP and MMP-9 were tested and compared after treatment. Results： Compared with before treatment, the CA125, ANP, BNP and MMP-9 levels were lower（P〈0.05）, the TIMP-1 level were higher（P〈0.05）. Compared with the control group after treatment, the CA125 level（34.05±4.63）,ANP level（216.98±27.65）, BNP level（437.62±45.26）and MMP-9 level（550.17±65.15）were lower（P〈0.05）, the TIMP-1level（182.32±21.78）were higher（P〈0.05）. Conclusion： Digoxin tablets can improve cardiac function in elderly patients with chronic heart failure, and it may be related to the decrease of serum CA125, BNP, ANP, MMP-9 and TIMP-1 levels in elderly patients with chronic heart failure.

关 键 词：地高辛片 慢性心力衰竭 CA125 BNP MMP-9 

分 类 号：R541.61[医药卫生—心血管疾病]